News Doubts over BACE drugs after Merck ends Alzheimer's trial Decision comes a year after Merck axed EPOCH verubecestat trial
News Axovant CEO David Hung quits after Alzheimer's drug failure Last month the biotech Axovant was rocked by the failure of its star drug intepirdine in Alzheimer’s disease – and the fall-out is still being felt, with CEO David Hung deciding to walk out.
News Boehringer latest to axe Alzheimer's drug Company will trial BI 409306 in schizophrenia instead.
News Bad week for dementia R&D after Axovant howler and another f... Axovant misreports trial results, Lundbeck Alzheimer's drug fails
News Pfizer axes Alzheimer's and Parkinson's research Big pharma will continue developing tanezumab painkiller with Lilly
Partner Content Partner Content 2018 Agenda Released: World CNS Summit Targeting Neurodegenerative Diseases
News GBL joins CVC in €10.7bn takeover bid for Recordati A consortium of investors has made a €10.7bn offer to take Italian pharma Recordati private, but some analysts are sceptical the deal will go through.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
